A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
Clinical trial NCT06460324 · COMPLETED
Trial details
- NCT number
- NCT06460324
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-05-20
- Primary completion
- 2023-07-03
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.